Related references
Note: Only part of the references are listed.The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
J. R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas
Casilda Balmaceda et al.
CANCER (2008)
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma
Bart Neyns et al.
CANCER INVESTIGATION (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Manuela Caroli et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide
Olivier L. Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine
W. P. Roos et al.
ONCOGENE (2007)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death
RN Trivedi et al.
CANCER RESEARCH (2005)
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience
W Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme - Phase I/II study
SE Combs et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide
M Brada et al.
ANNALS OF ONCOLOGY (2005)
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
H Athanassiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide:: A toxicity with therapeutic implications
YB Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-primidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy
T Kamiryo et al.
NEUROSURGERY (2004)
Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas
JL Blanc et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
One week on/one week off:: A novel active regimen of temozolomide for recurrent glioblastoma
W Wick et al.
NEUROLOGY (2004)
O-6-benzylguanine suppression of O-6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
SC Schold et al.
NEURO-ONCOLOGY (2004)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Pharmacological strategies to increase the antitumor activity of methylating agents
L Tentori et al.
CURRENT MEDICINAL CHEMISTRY (2002)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Unmasking a killer:: DNA O6-methylguanine and the cytotoxicity of methylating agents
M Bignami et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
